Ibudilast D7

Ibudilast D7 is a deuterated derivative of Ibudilast, a drug that has been used in Japan for over 20 years to treat asthma, stroke, and other neurological conditions. Ibudilast D7 is a selective inhibitor of phosphodiesterase-4 (PDE4), an enzyme that degrades cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in cells. This inhibition of PDE4 increases levels of cAMP and cGMP, leading to a reduction in inflammation and other cellular responses. Ibudilast D7 has been used in preclinical research to study the effects of PDE4 inhibition on various diseases, including multiple sclerosis, Alzheimer's disease, and substance abuse disorders. It has shown promise in reducing inflammation and neurodegeneration, and has been suggested as a potential treatment for these conditions. Chemically, Ibudilast D7 is a labeled compound, meaning that it contains seven deuterium atoms instead of hydrogen atoms. This labeling allows for easier detection and quantification of the drug in biological samples. The chemical formula of Ibudilast D7 is C14H8D7N2O, and its molecular weight is 216.29 g/mol. In conclusion, Ibudilast D7 is a selective PDE4 inhibitor that has shown promise in preclinical research for the treatment of various diseases. Its chemical labeling allows for easier detection and quantification, making it a valuable tool in research.